When should mupirocin ointment be administered for superficial bacterial skin infections (e.g., impetigo, minor wound infections) or nasal Staphylococcus aureus/MRSA colonization?

When to Give Mupirocin Ointment

Mupirocin 2% ointment should be applied three times daily for minor superficial bacterial skin infections such as impetigo and secondarily infected lesions (eczema, ulcers, lacerations) in children, or intranasally twice daily for 5 days each month to eradicate nasal Staphylococcus aureus colonization in patients with recurrent furunculosis. 1, 2

Primary Indications for Topical Mupirocin

Minor Skin Infections in Children

• Mupirocin 2% topical ointment is specifically recommended for children with minor skin infections such as impetigo and secondarily infected skin lesions including eczema, ulcers, or lacerations. 1
• Apply a small amount to the affected area three times daily, with optional gauze dressing coverage. 2
• Re-evaluate patients who do not show clinical response within 3 to 5 days. 2

Impetigo (Primary Superficial Skin Infection)

• For localized and nonbullous impetigo, topical mupirocin may be used as first-line therapy. 1
• Mupirocin demonstrates excellent efficacy in impetigo, with at least 80% of patients achieving clinical cure or marked improvement and over 90% eradication of the bacterial pathogen. 3
• The drug has excellent in vitro activity against staphylococci and most streptococci, the primary pathogens in impetigo. 3, 4

Superficial Wound Infections

• Mupirocin is effective for treating superficial primary and secondary skin infections, particularly infected wounds. 3, 4
• Clinical trials documented that mupirocin was significantly better than vehicle alone and as effective as oral antibiotics (cloxacillin, dicloxacillin, erythromycin) for wound infections caused by gram-positive pathogens. 4

Nasal Decolonization Strategies

Recurrent Furunculosis Prevention

• For patients with recurrent furunculosis and nasal S. aureus colonization, apply mupirocin ointment twice daily in the anterior nares for the first 5 days each month. 1
• This regimen reduces recurrences by approximately 50%. 1
• The prevalence of nasal staphylococcal colonization in the general population is 20–40%, but only some carriers develop recurrent skin infections. 1

MRSA Outbreak Control

• During outbreaks of community-acquired MRSA (CA-MRSA) in sports teams or close-contact settings, topical nasal mupirocin therapy (twice daily for 5–7 days) may be used among colonized individuals to limit spread. 1
• Intranasal 2% calcium mupirocin achieves elimination of S. aureus, including MRSA, in over 95% of subjects in bacteriologically controlled studies. 5
• However, high-level mupirocin resistance (MIC >512 µg/mL) has been associated with subsequent decolonization failure. 1

Healthcare Worker and Hospitalized Patient Decolonization

• Mupirocin calcium ointment (0.5 g inserted into each nostril twice daily for 5 days) is FDA-approved for eradicating nasal MRSA colonization in adult patients and healthcare workers as part of comprehensive infection-control programs during institutional outbreaks. 6
• Placebo-controlled studies demonstrate mupirocin's ability to eliminate nasal carriage of S. aureus in healthcare workers. 6

Recurrent SSTI Prevention in Household Settings

• For patients with recurrent skin and soft tissue infections (SSTIs), nasal and topical body decolonization of asymptomatic household contacts may be considered following treatment of active infection. 1
• Symptomatic contacts should be evaluated and treated; decolonization strategies may be considered after treating active infection. 1

When NOT to Use Mupirocin

Extensive Burns

• Mupirocin in its polyethylene glycol base should only be used on burns of less than 20% total body surface area, applied for a limited period of 5 days. 7
• The safety and efficacy in burns exceeding 20% total body surface area have not been established. 7

Systemic Infections Requiring Oral/IV Antibiotics

• Mupirocin undergoes rapid systemic metabolism and will only be used topically; it cannot replace systemic antibiotics for deeper or more extensive infections. 3, 4
• For superficial incisional surgical site infections that have been opened, antibiotics are usually not needed unless systemic inflammatory response criteria or organ failure signs are present. 1

Simple Abscesses Without Surrounding Cellulitis

• Incision and drainage is the primary treatment for simple abscesses or boils; antibiotics (including topical mupirocin) are not recommended for simple abscesses. 1

Mechanism and Spectrum of Activity

• Mupirocin inhibits bacterial protein and RNA synthesis by reversibly binding to isoleucyl-transfer RNA synthetase. 3, 4
• It has excellent activity against staphylococci and most streptococci but less activity against other gram-positive and most gram-negative bacteria. 3
• Its novel chemical structure and unique mechanism make cross-resistance with other topical antibacterial agents less likely. 3

Adverse Effects and Tolerability

• Side effects are limited to local reactions (in less than 3% of patients) and are no more frequent than observed with vehicle alone. 3
• Mild to moderate adverse events include respiratory problems and nasal effects (erythema, swelling, burning/stinging, pruritus, dryness). 6
• Treatment is generally well tolerated in both children and adults. 4, 7

Critical Caveats

• Do not use mupirocin as monotherapy for cellulitis or deeper skin infections requiring systemic antibiotics. 1
• Resistance surveillance is important; high-level mupirocin resistance can lead to decolonization failure. 1
• Mupirocin should be reserved for selective use when current prophylactic topical therapy has failed to control MRSA infection, applied only for limited periods (typically 5 days). 7
• For impetigo, erysipelas, and cellulitis, systemic antibiotics against gram-positive bacteria remain the primary treatment recommendation. 1